BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for TScan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:40 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% | 658,093 (+14.91%) | Filing |
| 2023-06-05 4:45 pm Purchase | 2023-05-26 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 4,414,910 9.990% | 4,414,910 (New Position) | Filing |